The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 

 

This Article
-Full Text
NEJM -- Steinbrook R. The Price of Sight -- Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration. 355(14):1409-12. Supplementary Audio

Interview with Frederick L. Ferris III on ranibizumab (Lucentis) and bevacizumab (Avastin) for age-related macular degeneration.

photo of Frederick Ferris
 

Supplement to: Steinbrook R. The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration. N Engl J Med 2006;355(14):1409-12.

Frederick L. Ferris III is clinical director of the National Eye Institute in Bethesda, Maryland.

Rachel Gotbaum, the interviewer, is an independent producer based in Boston.


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.